Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy
ObjectiveNon-alcoholic steatohepatitis (NASH) is a progressive liver disease with lipid accumulation, inflammation, and liver fibrosis. Ponatinib, a third-generation tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia, was found to improve metabolic disorders in mice. However, t...
Saved in:
Main Authors: | Zhuomiao Lin, Meiqing Yang, Xihui Yu, Guozhu Tan, Jiahong Zhong |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1505768/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TXNIP deficiency attenuates renal fibrosis by modulating mTORC1/TFEB-mediated autophagy in diabetic kidney disease
by: Yunxia Du, et al.
Published: (2024-12-01) -
Significance of Clinical-Pathological Correlation in Ponatinib Reactions
by: Judith Monserrat Corona Herrera, et al.
Published: (2025-01-01) -
AlphaFold-based AI docking reveals AMPK/SIRT1-TFEB pathway modulation by traditional Chinese medicine in metabolic-associated fatty liver disease
by: Lulu Zhang, et al.
Published: (2025-02-01) -
A soy glycinin derived octapeptide protects against MCD diet induced non-alcoholic fatty liver disease in mice
by: Peng Ma, et al.
Published: (2022-11-01) -
Association of Breastfeeding with Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in mothers: A cross sectional survey
by: Muhammad Zafar Majeed Babar, et al.
Published: (2024-06-01)